HeXun Biosciences Co., Ltd.

SL Science Holding Limited announced the successful exhibition of breakthrough preclinical research on a novel glioblastoma treatment at the 2026 World Congress of Basic and Clinical Pharmacology in Melbourne. The research, conducted with Taipei Medical University, JY BioMed, and HeXun Biosciences, showed that direct administration of gamma delta T cells achieved complete tumor elimination by day 26 post-treatment at the highest dose tested. The study demonstrated dose-dependent efficacy and a clean safety profile with no major adverse effects. SL Science's Chairman and CEO William Wang called the exhibition a monumental milestone, highlighting the platform's potential against challenging solid tumors.